Bendamustine, ASCS May Be Effective for Multiple Myeloma with Impaired Bone Marrow

Share this content:
Dose-intensified bendamustine followed by ASCS is safe, feasible for treatment of multiple myeloma with limited bone marrow reserve.
Dose-intensified bendamustine followed by ASCS is safe, feasible for treatment of multiple myeloma with limited bone marrow reserve.

Dose-intensified bendamustine followed by autologous blood stem cell support (ASCS) is safe and feasible for the treatment of patients with multiple myeloma who have very limited bone marrow reserve, a study published online early in the journal Hematological Oncology has shown.

Because therapeutic options are often very limited in heavily pretreated patients with relapsed/refractory multiple myeloma due to impaired bone marrow function, researchers sought to evaluate the effect of dose-intensified bendamustine followed by ASCS in patients with severely impaired hematopoiesis.

For the study, researchers identified 28 patients with multiple myeloma with a median of three prior lines of therapy.

RELATED: Minimal Benefit with Bortezomib, Dexamethasone as Maintenance Therapy for Multiple Myeloma

All patients had relapsed from the last treatment with impaired bone marrow function were ineligible for conventional chemotherapy, novel agents, or trial enrollment.

Patients received bendamustine 180mg/m2 on days 1 and 2, followed by ASCS.

Results showed that a minimal response was achieved in 36% of patients and 50% had stable disease disease. Researchers found that the median progression-free survival was limited to 2.14 months.

The authors note that the most significant finding was that patients were once again eligible for alternative treatments due to improved hematopoiesis.

Reference

  1. Breitkreutz I, Becker N, Benner A, et al. Dose-intensified bendamustine followed by autologous peripheral blood stem cell support in relapsed and refractory multiple myeloma with impaired bone marrow function. Hematol Oncol. 2015. [Epub ahead of print]. doi: 10.1002/hon.2199

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters